The New York Entrepreneur

Viking Therapeutics stock jumps 20% after drugmaker moves weight loss injection to late-stage trial

Read Time:9 Second

It brings the drugmaker one step closer to joining the market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade. 

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post UK’s Coinbase subsidiary fined $4.5 Million for high-risk customer breaches
Next post NYCB stock drops on steeper-than-expected losses on office and multi-family loans